Ascletis Pharma (ASCLF) Projected to Post Quarterly Earnings on Tuesday

Ascletis Pharma (OTCMKTS:ASCLF) is expected to release its results before the market opens on Tuesday, March 31st. Analysts expect Ascletis Pharma to post earnings of ($0.04) per share and revenue of $36.3060 million for the quarter.

Ascletis Pharma Price Performance

Shares of ASCLF stock opened at $1.81 on Friday. Ascletis Pharma has a 1-year low of $0.62 and a 1-year high of $2.29. The firm has a fifty day moving average of $1.92 and a two-hundred day moving average of $1.65.

Ascletis Pharma Company Profile

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical?stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small?molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct?acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).